<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058185</url>
  </required_header>
  <id_info>
    <org_study_id>CPP58-12, ID-RCB2012-A00791</org_study_id>
    <nct_id>NCT03058185</nct_id>
  </id_info>
  <brief_title>Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Obeservatory for PAtients With Laminopathies and Emerinopathies)</brief_title>
  <acronym>OPALE</acronym>
  <official_title>Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Obeservatory for PAtients With Laminopathies and Emerinopathies)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pitié-Salpêtrière Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laminopathies and emerinopathies are complex group of rare disorders due to mutations in
      A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or
      cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a
      major cause of death. Remarkable progress has been made in the description of the clinical
      and genetic spectrum of these diseases since the 1990's. Until now, precise
      phenotype/genotype relations remain elusive. As for several other neuromuscular disorders,
      apart from symptomatic treatments, there is currently no specific treatment to prevent or
      slow down the progression of the disease. The OPALE registry is a multicentre web-based
      registry dedicated to laminopathy and emerinopathy French patients. OPALE has been approved
      by ethical and regulatory authorities. Its main inclusion criteria is the presence of a
      proven pathogenic LMNA and/or EMD gene mutation.

      The OPALE objectives are to provide a tool allowing detailed capture of patient genetic,
      neurological, cardiological, endocrinological and respiratory assessments, in order to allow
      i) precise disease natural history, ii) evaluation of different disease complication
      frequency and iii) identification of prognosis factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2013</start_date>
  <completion_date type="Anticipated">July 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <description>Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression</description>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Laminopathies</condition>
  <condition>Emerinopathies</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a proven pathogenic LMNA and/or EMD gene mutation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of a proven pathogenic LMNA and/or EMD gene mutation

          -  Regular followup in France.

          -  Signed informed consent

        Exclusion Criteria:

        -Signed informed refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Cathy CHIKHAOUI</last_name>
    <phone>+33142165873</phone>
    <email>k.chikhaoui@institut-myologie.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de référence des maladies neuromusculaires, Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <state>Yvelines</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Quijano-Roy, MD, PhD</last_name>
      <email>susana.quijano-roy@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ivana Dabaj, MD</last_name>
      <email>ivana.dabaj@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service d'endocrinologie, diabétologie et endocrinologie de la reproduction, Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Vigouroux, MD, PhD</last_name>
      <email>corinne.vigouroux@inserm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Camille Vatier, MD, PhD</last_name>
      <email>camille.vatier@inserm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre de référence maladies neuromusculaires, GH Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Chikhaoui</last_name>
      <phone>+33142165873</phone>
      <email>k.chikhaoui@institut-myologie.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de cardiologie, Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Duboc, MD, PhD</last_name>
      <email>denis.duboc@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Karim Wahbi, MD, PhD</last_name>
      <email>karim.wahbi@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://epidemiologie-france.aviesan.fr/epidemiologie-france/fiches/observatoire-des-patients-atteints-de-laminopathies-et-emerinopathies</url>
    <description>Portail épidémiologie France</description>
  </link>
  <link>
    <url>http://www.orpha.net/consor/cgi-bin/ResearchTrials_RegistriesMaterials.php?lng=FR&amp;data_id=115641&amp;Nom%20du%20registre%20ou%20mat%E9riel=Observatoire-des-patients-atteints-de-laminopathies-et-emerinopathies&amp;title=Observatoire-des-patients-atteints-de-laminopathies-et-emerinopathies&amp;search=ResearchTrials_RegistriesMaterials_Simple</url>
    <description>Orphanet</description>
  </link>
  <link>
    <url>http://www.afm-telethon.fr/observatoire-opale-6702</url>
    <description>AFM-Telethon</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pitié-Salpêtrière Hospital</investigator_affiliation>
    <investigator_full_name>Bruno Eymard</investigator_full_name>
    <investigator_title>Clinical Professor-Head of the neuromuscular reference center</investigator_title>
  </responsible_party>
  <keyword>Lamin A/C</keyword>
  <keyword>Emerin</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

